We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Use the filters below to narrow your search.
Filter results
You can narrow down the results using the filters.
Product type
Topic
- Advertising (272)
- COVID-19 (163)
- Safety monitoring and information (96)
- Legislation (93)
- Compliance and enforcement (65)
- Manufacturing (52)
- Vaping hub (51)
- Labelling and packaging (35)
- Scheduling (national classification system) (27)
- Import and export (26)
- Medicinal cannabis hub (25)
- Sunscreens (16)
- Shortages and supply disruptions (14)
- Weight loss products (14)
- Committees and advisory bodies (9)
- Cosmetics (5)
- Unique Device Identification (UDI) hub (4)
- Clinical trials (3)
- Fees and payments (2)
- Prescription opioids hub (2)
- Urogynaecological (transvaginal) surgical mesh hub (2)
- Breast implant hub (1)
Search
98 result(s) found, displaying 51 to 75
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesThe TGA has approved the first two nasal combination self-tests (for use at home) that detect both COVID-19 and influenza viral infections in humans.
-
Media releasesTGA provisionally approves Moderna bivalent COVID-19 vaccine for use as a booster dose in adults
-
Regulatory decision noticesThe TGA has provisionally approved Moderna's bivalent COVID-19 vaccine, elasomeran/imelasomeran (SPIKEVAX Bivalent Original/Omicron) for use as a booster dose in adults 18 years and over.
-
Regulatory decision noticesThe TGA has granted provisional approval to Biocelect Pty Ltd (on behalf of Novavax Inc) for its COVID-19 vaccine, NUVAXOVID.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Media releasesTGA commences evaluation of Pfizer's COVID-19 vaccine (COMIRNATY) for children aged 6 months to less than 5 years
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
Regulatory decision noticesThe TGA has provisionally approved the Pfizer Australia Pty Ltd COVID-19 vaccine, COMIRNATY, for use as a booster in individuals aged 12 to 15 years old.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsTGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.
-
COVID-19 vaccine safety reportsInformation about the TGA's safety monitoring of COVID-19 vaccines.